These findings suggest potential relevance not just for longevity, but also for regenerative medicine and age-related tissue repair
We think Amgen's going to be an important participant in this global health crisis. Amgen joins an increasingly competitive field: Eli Lilly recently saw its chronic weight product, injectable ZepBound (tirzepatide), approved by the FDA, while Novo Nordisk already has two weight-loss peptides on the market, Saxenda (liraglutide) and Wegovy (semaglutide)
Although the reasons for the variation are still unclear, this might be due to several differences in the individual study design and patient characteristics rather than drug effect [21]
Taking Wegovy at the same time as other medications
Based on the available evidence, cagrilintide appears to have a more favorable body composition profile, though the magnitude of difference between the two compounds remains to be determined through direct comparison studies